The Nippon India NIFTY Pharma ETF Growth Plan, managed by Nippon Life India Asset Management Limited, targets passive investment in the Nifty Pharma TRI, focusing on pharmaceutical sector securities.

Employing a replication strategy, the fund mirrors the Nifty Pharma TRI by investing proportionately in its constituent securities, ensuring alignment with benchmark performance.

The portfolio is heavily concentrated in pharmaceuticals, with top holdings like Sun Pharmaceutical Industries Limited at 22.2%, indicating significant sector exposure and potential concentration risk.

Over the past year, the fund has delivered a return of 3.2%, supported by a minimal tracking error of 0.02%, highlighting its effective benchmark alignment and risk management.

With an AUM of ₹1022.9 Cr and an expense ratio of 0.21%, the fund demonstrates cost efficiency while being managed by Jitendra Tolani, who brings 19 years of experience.